Ventijet Health Technology: Company Profile

Background

Company Overview

Ventijet Health Technology is a Spanish company specializing in advanced respiratory care solutions, focusing on personalized mechanical ventilation therapies. Established on October 27, 2020, the company is headquartered in Leioa, Bizkaia, Spain.

Mission and Vision

Mission: To transform mechanical ventilation into a personalized therapy based on objective data and advanced algorithms, aiming to reduce complications, shorten ICU stays, and optimize healthcare costs without compromising quality.

Vision: To become the reference standard in advanced ICU ventilation by integrating with leading ventilators and building a global network of respiratory data. The company plans to develop new therapies incorporating AI, digital twins, and predictive models to revolutionize critical patient care.

Industry Significance

Ventijet Health Technology operates in the medical device industry, specifically within the respiratory care sector. The company's innovative approach addresses critical challenges in mechanical ventilation, aiming to enhance patient outcomes and healthcare efficiency.

Key Strategic Focus

Core Objectives

Develop and commercialize advanced mechanical ventilation modes and monitoring systems.

Integrate AI and predictive analytics into respiratory care to personalize therapies.

Establish strategic partnerships with healthcare institutions to validate and implement their technologies.

Areas of Specialization

Continuous-flow ventilation modes.

Advanced respiratory monitoring systems.

Data analytics platforms for respiratory care.

Key Technologies Utilized

Continuous-flow ventilation technology.

Advanced respiratory monitoring algorithms.

Data analytics and AI-driven predictive models.

Primary Markets Targeted

Intensive Care Units (ICUs).

Hospitals and healthcare facilities.

Healthcare providers seeking advanced respiratory care solutions.

Financials and Funding

Funding History

Initial Capitalization: The company was established with an initial capital of €3,050.

Capital Increases:

June 21, 2021: Increased capital by €17,000, bringing the total to €20,050.

November 12, 2025: Increased capital by €18,525, bringing the total to €38,575.

February 5, 2026: Increased capital by €4,798, bringing the total to €43,373.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The raised capital is primarily allocated towards:

Research and development of new ventilation modes and monitoring systems.

Clinical trials and regulatory certifications.

Market expansion and strategic partnerships.

Pipeline Development

Key Pipeline Candidates

Ventijet Ventilation Mode: A continuous-flow ventilation mode designed to optimize mechanical ventilation in critically ill patients.

AVA Monitoring System: An advanced respiratory monitoring system that utilizes proprietary sensors and algorithms to provide real-time data on respiratory parameters.

Stages of Development

Ventijet Ventilation Mode: Completed clinical trials demonstrating safety and efficacy.

AVA Monitoring System: Achieved CE marking as a medical device, indicating compliance with European Union regulations.

Target Conditions

Acute Respiratory Distress Syndrome (ARDS).

Hypoxemic Respiratory Failure.

Anticipated Milestones

Expansion of clinical trials to further validate product efficacy.

Market launch and adoption in European healthcare facilities.

Technological Platform and Innovation

Proprietary Technologies

Continuous-Flow Ventilation: A novel ventilation mode that maintains a stable gas flow, adapting in real-time to the patient's physiology, improving ventilation homogeneity, and reducing pulmonary stress.

AVA Monitoring System: A system combining sensors and proprietary algorithms to measure advanced respiratory parameters, aiding in personalized therapy adjustments.

Significant Scientific Methods

Clinical Trials: Conducted to assess the safety and efficacy of Ventijet ventilation mode in patients with moderate ARDS.

Preclinical Studies: Performed to validate the viability and clinical value of the AVA monitoring system.

Leadership Team

Key Executives

Alexander Quintanilla Urionabarrenechea: Founder and CEO. He has been instrumental in establishing and leading the company since its inception.

Competitor Profile

Market Insights and Dynamics

The respiratory care market is experiencing growth due to increasing incidences of respiratory diseases, an aging population, and advancements in medical technology. The demand for innovative ventilation solutions is rising, presenting opportunities for companies like Ventijet Health Technology.

Competitor Analysis

ResMed: A global leader in sleep and respiratory care, known for its continuous positive airway pressure (CPAP) devices.

Philips Healthcare: Offers a range of ventilators and respiratory monitoring systems, emphasizing patient-centric solutions.

Getinge AB: Provides advanced ventilators and critical care equipment, focusing on improving patient outcomes.

Strategic Collaborations and Partnerships

Ventijet Health Technology has established collaborations with hospitals and reference entities that have expressed interest in further developing the project.

Operational Insights

Ventijet Health Technology differentiates itself through its innovative continuous-flow ventilation mode and advanced monitoring system, aiming to enhance patient outcomes and reduce healthcare costs.

Strategic Opportunities and Future Directions

The company plans to expand its product offerings, integrate AI and predictive analytics into respiratory care, and establish strategic partnerships to validate and implement their technologies in healthcare settings.